Stock Taper
PEN
PENUMBRA, INC.
NYSE
$321.68
▲ UP 0.21% (0.68)

KEY STATISTICS

Market Cap$12.67 B
52w High$362.41
52w Low$221.26
Dividend Yield
Frequency
P/E83.99
Volume234.13K
Shares Out.39.39M

COMPANY

LEADERSHIP

Adam Elsesser
CHIEF EXECUTIVE
Adam Elsesser

COMPENSATION 2026

Salary$850,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$1,620
Total$851,621

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 18, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
4,700

PRICE TARGET

Target High$320.00
Target Low$320.00
Target Median$320.00
Target Consensus$320.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$401.41M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2014-11-16Reverse1:10

PRICE

$321.68 ▲ UP 0.21% (+$0.68)
OVERLAYS
$322$322$322$3229:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM321.68

About Penumbra, Inc.

https://www.penumbrainc.com ↗

Penumbra, Inc. develops and markets innovative medical devices—including thrombectomy, neurovascular, and neurosurgical tools—for vascular and neurovascular treatments worldwide.

INDUSTRY

Medical - Devices

A PRODUCT PENUMBRA, INC. IS KNOWN FOR

Lightning Flash 3.0
Lightning Flash 3.0

Lightning Flash 3.0 is Penumbra's advanced CAVT system for rapid, efficient blood clot removal in veins and pulmonary arteries, featuring enhanced detection and automated backflush for faster, safer procedures.

Revenue by Products

IconPRODUCTQ4-2022Q1-2023Q2-2023Q3-2023
Neuro$91.54M $98.55M $108.81M $171.41M
Peripheral Vascular$129.68M $142.85M $152.68M $99.54M

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$275.03M $299.05M $296.39M $305.44M
NonUS$78.37M $84.6M
Other NonUS$79.66M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity4
Return On Assets5
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Lisa McClain
Lisa McClain
Sale (Full)
2025-07-10
Ro Khanna
Ro Khanna
Sale
2022-06-27

INSIDER TRADES

OFFICER: PRESIDENT
Narayan Shruthi
Purchase · 3.1K shares
2026-08-17
DIRECTOR, OFFICER: CEO
Elsesser Adam
Sale · 77.0K shares
2026-05-19
DIRECTOR
Grewal Harpreet
Sale · 100 shares
2026-04-02
OFFICER: PRESIDENT
Narayan Shruthi
Sale · 117 shares
2026-03-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 4
NEUTRAL 3
MARKET PERFORM 2
OUTPERFORM 1
SECTOR PERFORM 1
EQUAL WEIGHT 1
BUY 1
OVERWEIGHT 1
14 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
CRL$291.50COMPARE
BAX$26.13COMPARE
DVA$180.68COMPARE
ALGN$157.58COMPARE
GMED$82.97COMPARE
BIO$387.70COMPARE
HSIC$89.52COMPARE
HQY$96.37COMPARE